Novel specific hcv ns3 protease inhibitors

A compound of Formula (I):

• or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein
• J and J1 can be present or absent, and when present, are independently selected from lower alkyl (C1-C6), aryl, arylalkyl, alkoxy, aryloxy, heterocyclyl, heterocyclyloxy, keto, hydroxy, amino, arylamino, carboxyalkyl, carboxamidoalkyl, halo, cyano, formyl, sulfonyl, or sulfonamido;
• and
• R is alkyl (C1-C10), cycloalkyl (C3-C8), aryl, heteroaryl, or heterocyclyl.